Video Experimental Relacionado

Updated: Jul 8, 2026

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

11.1K

Amivantamab-Associated Vasculitis in a Patient With EGFR Exon 20 Insertion Non-Small Cell Lung Cancer: A Case Report

Daisuke Morinaga1, Megumi Furuta1, Doppo Fukui1

  • 1Department of Respiratory Medicine, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.

Clinical lung cancer
|February 22, 2026
PubMed
Resumen

No abstract available in PubMed .

Palabras clave:
eventos adversosAmivantamabreceptor bispecíficoinhibidor de punto de control inmunitariovasculitis

Más Videos Relacionados

A Patient-Derived Xenograft Model for Venous Malformation06:51

A Patient-Derived Xenograft Model for Venous Malformation

Published on: June 15, 2020

5.8K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.8K

Videos de Conceptos Relacionados

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...